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ZOLEDRONIC ACIDVERSUS ORALLY ADMINISTERED
BISPHOSPHONATES IN PREVENTION OF OSTEOPOROTIC
FRACTURES IN CZECH POST-MENOPAUSAL WOMEN
Tichopad A1, Kutscherauer P2
1CEEOR, Kirchheim b. München, Germany, 2Novartis, Prague, Czech
Republic
OBJECTIVES: Poor compliance with oral bisphosphonates
leads to increased risk of vertebral and hip fractures in
post-menopausal osteoporotic patients. Annual dose of
Zoledronic acid signiﬁcantly decreased risk of fractures as com-
pared to placebo. The objective of this study was to evaluate a
long-term cost-utility of the two strategies. METHODS: Markov
model was constructed and ﬁrst-order microsimulation was run
in order to compare long term health-economic impact of treat-
ments with Zoledronic acid and oral bisphosphonates in Czech
patients. Rather than clinical efﬁcacy, the model considered real-
life effectiveness of both treatments associated with medication
compliance. RESULTS: Compared to oral bisphosphonates the
treatment with Zoledronic acid showed systematically improved
effectiveness expressed as QALY gained throughout the life
expectancy. The incremental cost-effectiveness of the Zoledronic
acid is for 50 years of age below €25,708 per QALY gained and
decreases sharply for patients above 65 years, resulting in dis-
tinctly improved incremental cost-effectiveness ratio below
€6442 per QALY gained. CONCLUSIONS: From the age 65 on,
patients should be preferentially treated with Zoledronic acid
rather than oral bisphosphonates.
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COST-EFFECTIVENESS OF CELECOXIB COMPAREDTO
CONVENTIONAL NSAIDS AND NSAID+PPI COMBINATION
THERAPY IN RHEUMATOID ARTHRITIS
Inotai A, Meszaros A
Semmelweis University, Budapest, Hungary
OBJECTIVES: However, DMARDs are in the ﬁrst choice in the
treatment of rheumathoid arthritis (RA), several patients still
take NSAIDs, although, these drugs may cause serious gastro
intestinal (GI) side-effects under continuous use. COX2 inhibi-
tors supposed to have a better GI side-effect proﬁle. The aim of
our study was to evaluate the cost-effectiveness of the selective
COX2 inhibitor, celecoxib compared to conventional NSAIDs
and NSAID+PPI combination therapy. METHODS: A decision
tree model was developed, for one year, to simulate cohorts
within the three arms (celecoxib, NSAIDs, NSAID+PPI). Medical
costs, the costs of the side-effects (GI, cardio-vascular (CV)
events) and QALYs were calculated to gain ICER. One-way
deterministic sensitivity analyses were applied (tornado dia-
grams). Evaluations were made from a third party payer’s per-
spective. RESULTS: The results show that both NSAID+PPI
(ICER: €14,287/QALY) and celecoxib (ICER: €59,486/QALY)
offers extra health gain for extra money compared to NSAIDs.
NSAID+PPI seems to be the cost effective choice compared to
NSAID mono therapy. Celecoxib was dominated by NSAID+PPI
combination therapy. According to the sensitivity analyses
QALYs had the highest inﬂuence on ICER. CONCLUSIONS:
The selective COX2 inhibitor celecoxib seems to be an adequate
choice only for a limited group of patients with speciﬁc condi-
tions such as drug allergy or serious GI risk with no CV risk,
possibly with further PPI co-therapy.
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COST-UTILITY EVALUATION OFTHETREATMENT OF
PATIENTS WITH OSTEOARTHRITIS WITH INSAPONIFICATES
OF AVOCADO AND SOY (PIASCLEDINE®)
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OBJECTIVES: To determine the most cost-util alternative in the
chronic treatment of Osteoarthritis METHODS: A study of
cost-utility was performed that used as source of information for
efﬁcacy a systematic review of the literature and as source of
costs a microcosting was done of each of the states of health
of the outcomes expected with chronic treatment. The quality of
life was validated by a panel of experts. As analytical tool, a
Markov model was used. The alternatives in competence were
non-steroid anti-inﬂammatories and inhibitors of COX-2, as
well as Piascledine. As state of health, hemorrhage of the upper
digestive tube, acute myocardial infarction, vascular cerebral
event and nephropathy were considered. The perspective of the
study was the public health services, in this case the Instituto
Mexicano del Seguro Social (IMSS); The analysis was performed
with a temporal horizon of 10 years, with a 3% discounting rate
for costs and effectiveness. The sensitivity analysis was one-way,
two-way and probabilistic RESULTS: Piascledine is the alterna-
tive that offers more years of life adjusted for quality of life
(17.03 QALYs), insofar as the AINE’s offer 14.17 QALY’s and
the Cox-2 13.96 QALY’s. The cost per QALY, is lower with
Piascledine ($333 USD) in comparison with AINE’s and Cox-2
$3397.00 USD and $2841.00 respectively. Piascledine is domi-
nant over AINE’s and Cox-2. Piascledine offers more net
economic beneﬁts and net health beneﬁts independently of
willingness to pay. CONCLUSIONS: Piascledine is a dominant
treatment in the chronic treatment of osteosrthritis versus AINEs
and COX-2.
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OBJECTIVES: The selective T cell co-stimulation modulator
abatacept was approved by EMEA in 2007 for the treatment of
moderate to severe active RA patients with an insufﬁcient
response or intolerance to disease-modifying anti-rheumatic
drugs (DMARDs), including at least one tumor necrosis factor-
alpha antagonist (anti-TNF). The objective of this study was to
assess the cost-effectiveness of abatacept in RA patients with an
inadequate response to anti-TNFs in the Hungarian setting.
METHODS: An individual state transition simulation cost-
utility model based on disease progression expressed in Health
Assessment Questionnaire (HAQ) disability index score change
was developed to enrol patients corresponding to the patients of
the ATTAIN clinical trial. This cost-utility analysis was con-
ducted using a societal perspective, including all costs (direct and
indirect) related to RA. We also present results from the perspec-
tive of Hungarian health insurance, where RA-related direct
costs are the most relevant. In this cost-utility assessment, abata-
cept was compared to methotrexate (MTX), the most prescribed
DMARDs. Current treatment patterns showing that patients
with an insufﬁcient response or intolerance to a ﬁrst anti-TNF
agent are switched to a subsequent anti-TNF agent, abatacept
was also compared to cycled anti-TNFs based on data from the
British Society of Rheumatology Biologics Registry. The model
was populated with Hungarian cost, utility and epidemiological
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data. Costs and beneﬁts were discounted at 5% per annum as per
Hungarian guidelines. RESULTS: With reference to the ATTAIN
trial, and assuming a treatment duration of 1 year and 10 years
time horizon, abatacept was cost-effective compared to MTX,
yielding 0.57 additional QALY at an additional cost of 2.03
million HUF with an incremental cost-effectiveness ratio of 3.6
million HUF/QALY based on a societal perspective. From the
Hungarian health insurance perspective, the incremental cost-
effectiveness ratio was 4.4 million HUF/QALY gained. Com-
pared to cycled anti-TNFs, abatacept was dominant (more
effective and overall less costly), with a QALY gain of 0.48 and
estimated savings of HUF 731113. From the Hungarian health
insurance perspective, the savings were 479 815 HUF. The results
are robust to extensive sensitivity analyses. CONCLUSIONS:
The results of this cost-utility assessment suggest that abatacept
is cost-effective compared to MTX and to cycled anti-TNFs in
Hungary for the approved indication, and within the usual
acceptance cost-effectiveness ranges.
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GOLIMUMAB,A HUMAN ANTI-TNF-ALPHA MONOCLONAL
ANTIBODY, SIGNIFICANTLY REDUCESTIME LOST FROM
WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS:
POOLED RESULTS FROMTHREE PHASE 3 STUDIES
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Hsia EC5, Rahman MU5, Gathany T1, Han C1, Parasuraman S1
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OBJECTIVES: To evaluate the effect of golimumab (GLM) treat-
ment on time lost from work in rheumatoid arthritis (RA)
patients. METHODS: The effect of GLM on time lost from work
was evaluated in three multicenter, randomized, double-blind,
placebo (PBO)-controlled RA studies (GO-BEFORE,
GO-FORWARD, and GO-AFTER). Data from patients receiving
GLM or PBO with or without methotrexate (MTX) were
included. GLM SC injections of 50 mg or 100 mg were admin-
istered q4wks. Analyses were pooled to increase the power to
detect a difference between treatment groups. Time lost from
work was collected through a questionnaire at baseline and
q8wks through wk24. Time lost from work was summarized
cumulatively through wk16 and wk24 and compared between
groups using an ANOVA on van der Waerden normal scores. The
analysis was limited to patients <65 years of age and employed
full-time at baseline. The proportion of patients reporting no
days lost from work in the GLM +/-MTX group compared with
PBO +/-MTX was calculated and compared between groups
using chi-square test. RESULTS: There were signiﬁcant differ-
ences in time lost from work (days) for patients treated with
GLM +/-MTX through wk16 and wk24 compared with PBO +/-
MTX. At wk24, the PBO +/-MTX group had lost on average 6.9
 19.7 days compared with 5.0  19.4 days for the combined
GLM +/-MTX group, a difference of 1.9 days (p = 0.004). At wk
24, the 75th percentile for the combined GLM +/-MTX group
was 1.000 day (range 0–180) compared with 3.000 days (range
0–120) for the PBO +/-MTX group. A signiﬁcantly higher
proportion of patients in the combined GLM +/-MTX group
reported no time (days) lost from work compared with PBO
+/-MTX (73.1% vs. 60.7%; p = 0.002). CONCLUSIONS: GLM
+/-MTX signiﬁcantly reduced time lost from work for RA
patients compared with PBO +/-MTX. A signiﬁcantly higher
proportion of patients in the GLM group reported no time lost
from work compared with PBO +/-MTX.
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PARAMEDICAL OR ALTERNATIVETREATMENTS AND
ASSOCIATED COSTS FORTHE MANAGEMENT OF
FIBROMYALGIA IN FRANCE
Maugars Y1, Lamotte M2,Van Vlaenderen I3, Le Lay K4,Taieb C4
1Hotel Dieu, Nantes, France, 2IMS Health, Brussels, Belgium, 3IMS
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OBJECTIVES: To describe the multidisciplinary outpatient man-
agement of ﬁbromyalgia and the paramedical resources and alter-
native treatments used in France, METHODS: A French expert
panel, involving 33 general practitioners (GP) and 27 rheuma-
tologists, was asked to describe their prescribed paramedical care
and other alternative treatments in ﬁbromyalgia patients, by
means of a questionnaire covering a period of four years before
diagnosis to four plus years after diagnosis, with 1-year intervals.
Average reported prescriptions were calculated. Costs were cal-
culated by multiplying prescribed resource use with correspond-
ing French unit costs (€; 2007; societal perspective). RESULTS:
Paramedical resource use and other alternative treatments
increase substantially as from year from four years untill the ﬁrst
year after diagnosis, and slightly decrease in the subsequent
years. In the ﬁrst year after ﬁbromyalgia diagnosis, 20% of the
panel prescribes various food supplements in 59% of their
patients (average duration varying between 8 and 52 weeks);
93% prescribes physiotherapy in 63% of their patients (average
duration of 14 weeks); 57% prescribes thermal baths in 23% of
their patients (3 weeks); 55% prescribes acupuncture in 30% of
their patients (14 weeks); 48% prescribes chiropractor therapy in
28% of their patients (8 weeks); 55% prescribes relaxation
therapy in 24% of patients (17 weeks); 37% prescribes psycho-
analysis in 21% of patients (28 weeks); 20% prescribes hypno-
therapy in 16% of patients (9 weeks); 8% prescribes biofeedback
in 16% of patients (20 weeks). The average cost from a societal
perspective is estimated at €387 per patient per year, ranging
from €265 before diagnosis (4 year period), over €678 in the year
following diagnosis, towards €453 in the period after diagnosis
(3 year period). CONCLUSIONS: Paramedical and alternative
treatment of ﬁbromyalgia represents 387 euros per patient and
per year from the societal perspective. Resource use and costs
steadily increase till the year following diagnosis and decline
afterwards.
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OUTPATIENT MEDICAL MANAGEMENT OF FIBROMYALGIA IN
FRANCE COMPAREDTOTHE UNITED KINGDOM
Maugars Y1, Lamotte M2,Van Vlaenderen I2, Le Lay K3,Taieb C3
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OBJECTIVES: To describe and compare the outpatient medical
management of ﬁbromyalgia patients in France and United-
Kingdom, METHODS: A French expert panel, involving 33
general practitioners (GPs) and 27 rheumatologists, was ques-
tioned in 2007 by means of a questionnaire describing the UK
prescriptions registered in the General Practice Research Data-
base between January 1998 and March 2003. Participating
experts were asked to describe their own clinical practice com-
pared to the UK prescriptions in terms of diagnostic tests, drugs,
consultations and referrals. over a period of four years before
diagnosis to four plus years after diagnosis using one year inter-
vals. Average reported prescriptions were calculated and com-
pared to the UK data. RESULTS: Interviewed experts monitor on
average 36 [24–49] ﬁbromyalgia patients, of whom 38% [31–47]
for at least 4 years. Their patients have an average age of 48
[47–49] (vs 49 in UK), 86% [84–88] are women (vs 81% in UK).
French physicians are 74.4% [73.3–75.6] likely to validate the
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